LBA61Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC). (23rd October 2018) - Tan, D S; Kim, S-W; Sequist, L V; Ponce Aix, S; Smit, E F; Hida, T; Yang, J C-H; Felip, E; Seto, T; Grohe, C; Wolf, J; Ko, J; et al.